Latest news with #Pegfilgrastim
Economic Times
6 days ago
- Business
- Economic Times
Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million
Synopsis Intas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. This acquisition strengthens Intas's position as a global leader in pegfilgrastim. Accord BioPharma, Intas's U.S. specialty business, will continue commercializing UDENYCA to reduce infection risk in cancer patients undergoing myelosuppressive chemotherapy. Agencies Intas Pharma has completed the acquisition of UDENYCA for $558 million, the company said in a release. UDENYCA is a biosimilar to Neulasta or Pegfilgrastim. It is used to treat side effects of radiation therapy in cancer patients such as recurrent infections. Intas acquired the biosimilar drug from California-based Coherus Life Sciences in December 2024.'This acquisition cements our position as a global leader in pegfilgrastim and allows us to further expand our specialty division across key international markets,' said Binesh Chudgar, Intas Pharma's chairman and managing Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, have acquired UDENYCA. With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia, the company's release stated.'The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavour to innovate and expand in the biosimilar space,' said Chrys Kokino, President, USA, Accord BioPharma.
Time of India
6 days ago
- Business
- Time of India
Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million
Intas Pharma has completed the acquisition of UDENYCA for $558 million, the company said in a release. UDENYCA is a biosimilar to Neulasta or Pegfilgrastim . It is used to treat side effects of radiation therapy in cancer patients such as recurrent infections. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program Intas acquired the biosimilar drug from California-based Coherus Life Sciences in December 2024. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Top 15 Most Beautiful Women in the World Undo 'This acquisition cements our position as a global leader in pegfilgrastim and allows us to further expand our specialty division across key international markets,' said Binesh Chudgar, Intas Pharma's chairman and managing director. Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, have acquired UDENYCA. Live Events With the acquisition, Accord BioPharma , the U.S. specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia, the company's release stated. 'The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavour to innovate and expand in the biosimilar space,' said Chrys Kokino, President, USA, Accord BioPharma.
Business Standard
24-06-2025
- Health
- Business Standard
Biocon Biologics partners with National Cancer Society of Malaysia
To launch a Patient Assistance Program (PAP) in Malaysia Biocon Biologics has partnered with the National Cancer Society of Malaysia (NCSM), a prominent not-for-profit cancer organization, to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia. Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia. The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints. The MoU was signed during the National Cancer Congress Malaysia 2025 event, emphasizing a commitment to improving patient-centric healthcare.
BusinessToday
24-06-2025
- Health
- BusinessToday
National Cancer Malaysia Partners Biocon In Offering Affordable Cancer Care For The Underserved
Biocon Biologics Limited, has partnered with the National Cancer Society of Malaysia to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia. The partnership will see Biocon Biologics providing quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia. The program will start with providing Trastuzumab to cancer patients facing treatment delays due to budget constraints. Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics, said, 'Together, we hope to positively impact thousands of lives and strengthen Malaysia's efforts to deliver inclusive, patient-centric healthcare.' Biocon Biologics aims to build on its previous success in expanding access to diabetes care in Malaysia, having served over 345,000 patients, and is now focusing on oncology through strategic partnerships like this. Related
Business Upturn
24-06-2025
- Business
- Business Upturn
Biocon Biologics partners with NCSM to launch Cancer Patient Assistance Program in Malaysia
By Aman Shukla Published on June 24, 2025, 08:56 IST Biocon Biologics Limited, a global biosimilars company and a subsidiary of Biocon Ltd., has joined hands with the National Cancer Society of Malaysia (NCSM) to launch a new Patient Assistance Program (PAP). This initiative aims to improve access to affordable, high-quality cancer treatments for underserved patients in Malaysia. Through this partnership, Biocon Biologics will supply biosimilar medicines from its oncology portfolio, including Trastuzumab, Pegfilgrastim, and Bevacizumab, to support cancer treatment in the country. The program will be managed by NCSM, which will oversee patient enrollment and the distribution of medicines as part of its broader healthcare services. The initiative will begin with the distribution of bTrastuzumab to breast cancer patients who are currently facing treatment delays due to budget limitations. The Memorandum of Understanding (MoU) was officially signed during the National Cancer Congress Malaysia 2025 , underscoring both organizations' commitment to advancing patient-centric healthcare and strengthening cancer care infrastructure in Malaysia. Biocon Biologics brings its global expertise in biosimilars to the partnership, while NCSM contributes its extensive experience in community outreach and patient support. Together, they aim to reduce the treatment burden for patients and make life-saving therapies more accessible. This program builds on Biocon Biologics' earlier success in Malaysia, where it provided insulin therapy and support to over 345,000 diabetes patients. The company is now extending its focus to oncology, using strategic collaborations to expand its impact on public health. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
